Targeting Tuberculosis: Novel Scaffolds for Inhibiting Cytochrome bd Oxidase.

Area of Science:

• Biochemistry
• Microbiology
• Drug Discovery

Background:

• Cytochrome bd oxidase, discovered in the 1920s, is a vital terminal oxidase found exclusively in prokaryotes.
• Its atomic structure determination in 2016 has revitalized interest in cytochrome bd as a potential drug target, particularly for Mycobacterium tuberculosis (Mtb).
• Previous research primarily focused on quinone analogues, such as Aurachin D, for inhibiting cytochrome bd.

Purpose of the Study:

• To identify novel inhibitor scaffolds for cytochrome bd in Mycobacterium tuberculosis.
• To explore new therapeutic avenues for treating tuberculosis by targeting this essential prokaryotic enzyme.

Main Methods:

• Computational screening was employed to identify potential cytochrome bd inhibitor scaffolds.
• In vitro assays were utilized to confirm the on-target activity of the identified compounds.

Main Results:

• Six novel inhibitor scaffolds for cytochrome bd were discovered through computational screening.
• The identified scaffolds demonstrated confirmed on-target activity in in vitro testing.
• These new scaffolds represent promising starting points for further lead optimization.

Conclusions:

• The identified cytochrome bd inhibitor scaffolds offer new therapeutic strategies against Mycobacterium tuberculosis.
• These findings open new avenues for developing novel anti-tuberculosis drugs targeting cytochrome bd.
• Further optimization of these scaffolds could lead to effective Mtb therapeutics.